News | Radiation Therapy | April 22, 2021

A Norwegian study for the first time reveals benefit of the PARP inhibitor Olaparib in patients with early breast cancer not harboring germline mutations

 

A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images


April 22, 2021 — Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate, shows a study from the University of Bergen, Norway (UiB).

PARP (Poly (ADP-ribose) polymerase) inhibitors represent an established targeted therapy for multiple cancer types, including cancers of the prostate, ovary and rare cases of breast cancer.

PARP inhibitors take advantage of defects in a central mechanism of DNA damage repair, observed in these cancers. While such compounds have been successfully applied in ovarian and prostate cancers, to this end only a small minority of patients with breast cancer (2-3%), harboring germline mutations in the BReast CAncer type-1 and -2 (BRCA1/2) genes have benefitted, and a seminal study conducted 12 years ago reveled no benefit for patients with breast cancer not harboring such mutations.

Now, a national Norwegian study headed by professors Hans Petter Eikesdal, Stian Knappskog and Per Eystein Lønning at University of Bergen and Haukeland University Hospital for the first time reveals benefit of the PARP inhibitor Olaparib in patients with early breast cancer not harboring germline mutations.

Poor prognosis — considerable results

In the PETREMAC study, unselected patients with large (>4 cm diameter) so-called triple negative breast cancers were treated upfront with Olaparib.

Triple negative breast cancers is a breast cancer subgroup often affecting young patients and is a form of breast cancer associated with a poor prognosis.

Among 32 patients treated, 18 (56%) responded with tumor regression on Olaparib monotherapy. Most importantly, 16 out of the 18 responders revealed molecular markers predicting a likely benefit (gene mutations or so-called epigenetic modifications) of genes involved in the process of DNA repair contrasting only 4 out of 14 non-responders.

These findings allow identification of individual tumors likely to benefit from PARP inhibition. Five patients harbored germline mutations (i.e. patients that may potentially be treated with a PARP inhibitor prior to this study).

However, among patients not harboring such germline mutations (i.e. patients that would normally be excluded from PARP inhibitor therapy), 14/26 patients (54%) responded to therapy. Moreover, among these 14 patients, 12 could be identified upfront as likely responders based on analyzing their tumor tissue for mutations / epimutations affecting DNA repair.

Improved personalized treatment

In conclusion, the study challenges the previous dogma that PARP inhibition may not work for patients not harboring germline mutations. Most importantly, the authors found a strong correlation between response to therapy and molecular markers easily detectable in the tumor tissue.

"While the results need confirmation in independent studies, our results point toward improved personalized treatment for many patients diagnosed with triple negative breast cancer", says professor Lønning.

Finally, the study illuminates a concept gaining increasing support in oncology: While previous studies revealed no benefit from PARP inhibition in late-stage breast cancer, this study demonstrates a therapy which was ineffective in late cancer may potentially be of great benefit in the early setting.

For more information: www.uib.no/

Related Content

News | Ultrasound Imaging

October 15, 2021 — NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung, introduces the V8; a high-end ...

Time October 15, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Breast Imaging

October 14, 2021 — Delphinus Medical Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) has ...

Time October 14, 2021
arrow
News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | MRI Breast

October 7, 2021 — An automated system that uses artificial intelligence (AI) can quickly and accurately sift through ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Subscribe Now